血液腫瘍―MIC-M診断から治療まで―

出版社: 先端医学社
著者:
発行日: 2005-12-20
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 4884072200
電子書籍版: 2005-12-20 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

6,050 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,025 円(税込)

商品紹介

検査・診断法から治療選択までを網羅した、血液腫瘍にかかわる医療従事者のための教科書。各検査法による染色写真を集めたカラー図譜も収載。本書ではMIC-Mにもとづいた、血液腫瘍の検査・診断法から治療までをわかりやすく解説。血液腫瘍の検査・診断にかかわるすべての医療従事者必読の一冊。

目次

  • 血液腫瘍―MIC-M診断から治療まで―

    ―目次―

    PART1●血液腫瘍の診断
     1.血液腫瘍の臨床検査総論
     2.WHO分類とMIC-M診断
     3.診断法と結果の解釈
      A.細胞形態と組織診断
       a.白血病の形態学的診断
       b.悪性リンパ腫
      B.フローサイトメトリー
      C.細胞遺伝学的診断
       a.染色体分染法
       b.蛍光in situ分子雑種(FISH)法
       c.多色染色体解析(SKY)法
      D.遺伝子診断
       a.核酸増幅検査
       b.サザンブロット法とノザンブロット法
       c.シーケンシング
       d.DNAマイクロアレイ

    PART2●MIC-M診断から治療選択へのアプローチ
     1.急性白血病
      A.成人
      B.小児
     2.骨髄異形成症候群
     3.慢性骨髄性白血病と骨髄増殖性疾患
     4.慢性リンパ性白血病
     5.悪性リンパ腫
      A.B細胞性リンパ腫
      B.T細胞性リンパ腫
      C.ホジキンリンパ腫
      D.消化管悪性リンパ腫
     6.多発性骨髄腫

    PART3●合併症の診断と治療
     1.血液腫瘍の感染症−正確な診断と適切な治療−
     2.抗癌剤の心毒性
      A.診断とリスク因子
      B.予防と治療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

PART 1 血液腫瘍の診断

P.39 掲載の参考文献
2) 青木延雄, 長谷川淳:DIC 診断基準の「診断のための補助的検査成績, 所見」 の項の改訂について. 厚生省血液凝固異常症調査研究斑昭和62年度研究報告書, 1998, pp. 37-41
3) 朝倉英策:スクリーニング検査. DIC の病態・ 診断とその対策, 中川雅夫編, 医薬ジャーナル社, 大阪, 1996, pp. 42-49
5) 広田健, 和賀一雄, 長島茂樹ほか:アミラーゼ産生形質細胞性腫瘍著明な筋肉内腫瘤を示した一例における遺伝子解析と文献的考察. 臨床血液 34:177-182, 1993
6) Hasenclever D, Diehl V:A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
8) 磯部敬:AL アミロイドーシス. アミロイドーシス, 磯部敬, 医学書院, 東京, 1997, pp. 44-66
10) 稲富由香, 後藤明彦, 栗山謙ほか:ASLO 著明高値を示した IgM 骨髄腫. 臨床血液 37:437-442, 1996
12) Bataille R, Boccadoro M, Klein B et al:C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737, 1992
13) 〆谷直人, 市川恵子, 鉢村和男ほか:C 反応性蛋白 (CRP) 低濃度域における血清アミロイドA 蛋白 (SAA) および IL-6 の変動について. 臨床病理 44:669-675, 1996
15) Yasuda N, Lai PK, Ip SH et al:Soluble interleukin2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71:1021-1026, 1988
16) 大野仁嗣, 石川隆之, 北島博之ほか:悪性リンパ腫診療における可溶性インターロイキン 2 受容体a鎖の重要性-他施設共同研究-. 臨床血液 43:170-175, 2002
17) 内藤和行, 山田一正:血液疾患における血清 thymidine kinase (s-TK) 活性値の臨床的検討. 癌と化学療法 15:3221-3226, 1988
18) 高橋直人, 中鉢明彦,:三浦偉久男ほか:本邦における成人リンパ腫関連血球貧食症候群. 臨床血液 40:542-549, 1999
19) Schiffer CA, Anderson KC, Bennett CL et al:Platelet transfusion for patients with cancer. Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
20) 日本臨床検査医学会:診断群別臨床検査のガイドライン 2003~医療の標準化に向けて~. 「日常初期診療における臨床検査の使い方小委員会J」編, 東京, 2003
P.62 掲載の参考文献
2) Bene MC, Castoldi G, Knapp W et al:Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9:1783-1786, 1995
3) World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, eds. by Jaffe ES, Harris NL, Stein H et al, IARC Press, Lyon, 2001
5) Greenberg P, Cox C, LeBeau MM et al:International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
6) Leukemia diagnosis 3, ed. by Bain BJ, Blackwell Scientific Publications, Oxford, 2003
P.71 掲載の参考文献
P.78 掲載の参考文献
1) Harris NL, Jaffe ES, Vardiman JW et al:WHO classification of tumours of haematopoietic and Lymphoid tissues:Introduction. In:Tumours of Haematopoietic and Lymphoid Tissues, IARC press, Lyon, 2001, pp.12-13
4) 須知泰山:リンパ節生検 基本的取扱い. 病理と臨床第12巻臨時増刊号:リンパ節病変, 菊池昌弘監修, 森茂郎, 北堅吉編, 文光堂, 東京, 1994, pp.49-52
5) 菊池昌弘:リンパ節生検診断:リンパ節診断の進め方. 病理と臨床 17:538-549, 1999
6) Nathwani BN, Hernandez AM, Drachenberg MR:Diagnostic significance of morphologic pattern of lymphoid proliferations in lymph nodes. In:Neoplastic hematopathlogy 2, ed. by Knowles DM, Lippincott Williams & Wilkins, Philadelpia, 2001, pp. 507-535
7) 悪性リンパ腫の病理診断の手引き集 http://pathol.nccgo.jp
8) Warnke R, Isaacson PG:Immunohistochemical analysis of lymphoid tissue. In:Neoplastic hematopathlogy 2, ed. by Knowles DM, Lippincott Williams & Wilkins, Philadelphia, 2001, pp.227-253
P.89 掲載の参考文献
1) 高本滋:原理.応用サイトメトリー,天神美夫監修,河本圭司ほか編,医学書院,東京,2000,pp.20-24
2) 米山彰子:フローサイトメトリー (細胞表面マーカー). スタンダード検査血液学, 日本検査血液学会編, 医歯薬出版, 東京, 2003, pp.158-165
5) Hata H,Xiao H,Petrucci MT et al:Interleukin-6 gene expression in multiple myeloma:a characteristic of immature tumor cells.BLood 81:3357-3364,1993
7) Reuss-Borst MA, Buhring HJ, Schmidt H et al:AML:immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 8:258-263, 1994
10) Inaba T, Shimazaki C, Sumikuma T et al:Flow cytometric analysis of Thy-1 expression in CD34-positive acute leukemia. Int J Hematol 66:315-323, 1997
11) Horn PA, Tesch H, Staib P et al:Expressiion of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 93:1435-1437, 1999
12) 日本臨床検査標準協議会,血液検査標準化検討委員会, フローサイトメトリーワーキンググループ:フローサイトメトリーによる造血器腫瘍表面抗原検査に関するガイドライン(JCCLS H2-PV1.0).日本臨床 ).日本臨床検査標準協議会雑誌 18:69-107,2003
14) Harada H, Kawano MM, Huang N et al:Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81:2658-2663, 1993
15) Picker LJ, Weiss LM, Medeiros LJ et al:Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol 128:181-201, 1987
17) Coustan-Smith E, Sancho J, Hancock ML et al:Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691-2696, 2000
19) Robertson LE, Huh YO, Butler JJ et al:Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone:clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29-36, 1992
20) 河本圭司, 塚崎裕司, 沼義博ほか:Laser Scanning Cytometer の画像. Medical Imaging Technology 17:197-202, 1999
P.93 掲載の参考文献
1) 腫瘍染色体アトラス, 阿部達生ほか編, 南江堂, 東京, 1986
2) 谷脇雅史:染色体分染法. 新染色体異常アトラス, 阿部達生ほか編, 南江堂, 東京, 1997, pp.18-30
3) 西田一弘:腫瘍細胞の染色体検査. 臨床染色体診断法, 古庄敏行編, 金原出版, 東京, 1996, pp.246-250
4) ISCN 1995:An International System for Human Cytogenetic Nomenclature, ed. by Mitelman F, Karger, Basel, 1995
P.105 掲載の参考文献
1) 谷脇雅史, 西田一弘:FISH 法. みんなに役立つ自血病の基礎と臨床, 大野竜三, 宮脇修一編, 医薬ジャーナル社, 大阪, 2004, pp.110-121
2) 谷脇雅史, 清水大介, 西田一弘:悪性リンパ腫の染色体・遺伝子異常 . 医学のあゆみ 212:301-306, 2005
3) 谷脇雅史, 西田一弘:骨髄異形成症候群の染色体異常 . 内科 94:451-456, 2004
6) Lichter P, Cremer T:Chromosome analysis by non-isotopic in situ hybridization. In:Human cytogenetics. A practical approach 1, eds. by Rooney DE et al, IRL Press, Oxford, 1992, pp 157-192
7) Nishida K, Tamura A, Nakazawa N et al:The immunoglobulin heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534, 1997
8) Yamashita Y, Okuda T, Nishida K et al:Recurrent chromosomal rearrangements at bands 8q24 and 11q13 in gastric cancer as detected by multicolor spectral karyotyping. World J Gastroenterol (in press)
13) 野村憲一:, 松本洋典, 谷脇雅史:びまん性大細胞型B細胞リンパ腫の診断における組織FISH法の意義. 血液・腫瘍科 47:314-319, 2003
15) 松本洋典, 野村憲一, 西田, 弘ほか (in preparation)
P.113 掲載の参考文献
P.118 掲載の参考文献
P.124 掲載の参考文献
2) 芹生卓:プロッテイング法. 血液・固形腫瘍診断マニュアル改訂版, 横田昇平編, フジメディカル出版, 大阪, 2002, pp. 12-23
3) 青木務:遺伝子発現の検出法. 改訂遺伝子工学実験ノート下, 田村隆明編, 羊土社, 東京, 1997, pp. 154-157
5) World Health Organization Classification of Tumour:Pathology and genetics of tumours of haematopoietic and lymphoid tissues, eds. By Jaffie ES et al, IARC Press, Lyon, 2001
6) 芹生卓, 横田昇平:T細胞受容体 (TCR) 遺伝子を用いたクローナリティ解析. 血液・腫瘍科 40 (supp13):572-579, 2000
7) 渡邊俊樹:HTLV-1. 病理と臨床 22 (suppl):S298-S304, 2004
8) 江角真理子:肝炎ウイルス. 病理と臨床 22 (suppl):S278-284, 2004
P.130 掲載の参考文献
P.135 掲載の参考文献
5) Tsutsumi S, Taketani T, Nishimura K et al:Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements, Cancer Res 63:4882-4887. 2003

PART 2 MIC-M診断から治療選択へのアプローチ

P.152 掲載の参考文献
3) Slovak ML, Kopecky KJ, Cassileth PA et al:Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
4) 谷脇雅史, 上田享司:白血病の分子発症機序. 日本内科学会雑誌 92:942-949, 2003
5) Grimwade D, Walker H, Oliver F et al:The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92:2322-2333, 1998
10) Hoelzer D, Gokbuget N:New approaches to acute lymphoblastic leukemia in adults:where do we go? Semin Oncol 27:540-559, 2000
11) Ohno R:How high can we increase complete remission rate in adult acute myeloid leukemia? Int J Hematol 72:272-279, 2000
12) Bishop JF, Matthews JP, Young GA et al:A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710-1717, 1996
14) 白血病・悪性リンパ腫治療プロトコール集, 大野竜三編, 医薬ジャーナル社, 大阪, 2001
15) Bloomfield CD, Lawrence D, Byrd JC et al:Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
P.162 掲載の参考文献
7) Cairoli R, Beghini A, Nadali G et al:Prognostic impact of c-Kit mutations in core binding factor-leukemia. Blood 104 (suppl):S2013, 2004
9) Kong XT, Ida K, Ichikawa H et al:Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21) (p11;q22) and identification of a novel transcript. Blood 90:1192-1199, 1997
10) Taki T, Ida K, Bessho F et al:Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 10:1303-1307, 1996
17) 小児血液・腫瘍疾患治療プロトコール集, 月本一郎 編, 医薬ジャーナル社, 大阪, 2003
20) 血液・固形腫瘍診断マニュアル, 横田昇平編, フジメディカル出版, 大阪, 2002
P.172 掲載の参考文献
2) World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, eds. by Jaffe ES, Harris NL, Stein H et al, Lyon, IARC Press, 2001
5) Greenberg P, Bishop M, Deeg J et al:NCCN Practice Guidelines for the Myelodysplastic Syndromes. Oncology 12:53-80, 1998
9) Greenberg P, Cox C, LeBeau MM et al:International scoring system for evaluating prognosis in myelodysplastic syndromes (Erratum in Blood 91:1100, 1998) Blood 89:2079-2088, 1997
11) Kaneko H, Misawa S, Horiike S et al:TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. Blood 85:2189-2193, 1995
16) Alessandrino EP, Amadori S, Barosi G et al:Italian Society of Hematology:Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87:1286-1306, 2002
17) Cheson BD, Bennett JM, Kantarjian H et al:Report ofan international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000
19) 中条達也:Low-risk MDSに対する免疫抑制療法:反応性のマーカー. 臨床血液 45:274-280, 2004
20) Okamoto T, Kanamaru A, Shimazaki C et al:Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG):results of an interim analysis. Int J Hematol 72:200-205, 2000
22) Sierra J, Perez WS, Rozman C et al:Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100:1997-2004, 2002
27) Appelbaum FR, Anderson J:Allogeneic bone marrow transplantation for myelodysplastic syndrome:outcomes analysis according to IPSS score. Leukemia 12 (suppl 1):S25-S29, 1998
28) List AF, Schiller GJ, Mason J et al:Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):Preliminary findings in a phase 2 clinical study. Blood 102:423a, 2003
29) Vey N, Dreyfus F, Guerci A et al:Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):Preliminary results in a phase 1/2 study. Blood 102:422a, 2003
31) Wijermans PW, Luebbert M, Verhoef G:LDH is an important risk factor to predict survival I patients with MDS treated with 5-aza-2'-deoxycytidine (decitabine). Blood 102:424a, 2003
34) List AF, Kurtin S, Glinsmann-Gibson BJ et al:Efficacy and safety of cc5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS). Blood 102:184a, 2003
P.181 掲載の参考文献
4) Rubin CM, Larson RA, Bitter MA et al:Association of a chromosomal 3;21 translocation with the blast phase of chronic myelogenous leukemia. Blood 70:1338-1342, 1987
6) Misawa S, Lee E, Schiffer CA et al:Association of the translocation (15;17) with malignant proliferation of promyelocytes in acute leukemia and chronic myelogenous leukemia at blastic crisis. Blood 67:270-274, 1986
7) 日本造血細胞移植学会:平成13年度全国調査報告書, 2001
8) O'Brien SG, Guilhot F, Larson RA et al:IRIS Investigators:Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
10) 日本造血細胞移植学会:造血幹細胞移植の適応ガイドライン:慢性骨髄性白血病. JSHCT monograph vol. 6, 2002
11) 谷脇雅史:慢性骨髄増殖性疾患. 造血器腫瘍アトラス第2版, 日本医事新報社, 東京, 1991, pp. 31-36
13) Murphy S, Peterson P, Iland H et al:Experience of the Polycythemia Vera Study Group with essential thrombocythemia:a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39, 1997
15) Murphy S:Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36 (Suppl 2):9-13, 1999
16) Cripe LD, Hromas R:Malignant disorders of megakaryocytes. Semin Hematol 35:200-209, 1998
17) Mertens F, Johansson B, Heim S et al:Karyotypic patterns in chronic myeloproliferative disorders:report on 74 cases and review of the literature. Leukemia 5:214-220, 1991
21) Macdonald D, Aguiar RC, Mason PJ et al:A new myeloproliferative disorder associated with chromosomal translocations involving 8p11:a review. Leukemia 9:1628-1630, 1995
22) Popovici C, Zhang B, Gregoire MJ et al:The t(6;8) (q27;pll) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 93:1381-1389, 1999
24) Guasch G, Mack GJ, Popovici C et al:FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9) (p12;q33). Blood 95:1788-1796, 2000
P.191 掲載の参考文献
1) Cheson BD, Bennett JM, Grever M et al:National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia:revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
2) Rai KR, Sawitsky A, Cronkite EP et al:Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
6) Molica S, Levato D, Dattilo A:Natural history of early chronic lymphocytic leukemia. A single institution study with emphasis on the impact of disease progression on overall survival. Haematologica 84:1094-1099, 1999
9) Richards SN et al:Do purine analogues improve survival? EHA2003 Abstract nr. 0620
10) Keating MJ, O'Brien S, Lerner S et al:Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998
13) Improved survival in patients with relapsed-refractory chronic lymphocytic leukemia (CLL) treated with Fludarabine, Cyclophosphamide, and Rituximab (FCR) combination. Blood 102 (suppl 1):110a, 2003
19) Byrd JC, Shinn C, Ravi R et al:Depsipeptide (FR901228):a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401-1408, 1999
22) Keating MJ. Lerner S. Kantarjian H et al:The serum B2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 86 (suppl 1):606a, 1995
24) Dohner H. Fischer K, Bentz M et al:p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B cell leukemias. Blood 85:1580-1589, 1995
26) Dohner H, Stilgenbauer S, James MR et al:11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89:2516-2522, 1997
28) Damle RN, Wasil T, Fais F et al:Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999
29) Hamblin TJ, Davis Z, Gardiner A et al:Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999
P.202 掲載の参考文献
1) World Health Organization classification of neo-plastic diseases of the hematopoietic and lymphoid issues, eds. by Jaffe ES et al, IARC Press, Lyon, 2001
6) AJCC cancer staging manual 6, eds, by AJCC et al, Springer-Verlag, New York 2002, pp. 393-403
17) Press OW:Treatment of mantle-cell lymphoma:sterm-cell transplantation, radioimmunotherapy, and manegement of mantle-cell lymphoma subsets. In:American Society of Clinical Oncology Educational book, ed. by Perry M, Alexandra, VA, American Society of Clinical Oncology and Lippincott Williams & Wilkins, Philadelphia, 2002, pp. 407-415,
22) Rosenwald A, Wright G, Chan WC et al:Lymphoma/Leukemia Molecular Profiling Project:The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
38) Link BK, Kahl B, Czuczman M et al:A phase II study of Apolizumab, a humanized monoclonal antibody, in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Oncology 16 (suppl 2):abstr 2540, 2002
40) Leonard JP, Coleman M, Vose J et al:Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma. Proc Am Soc Clin Oncol 22:566 abstr 2276, 2003
P.215 掲載の参考文献
1) Schichman SA, Aplan PD, Neri A et al:Pathogenesis of T-cell lymphomas. In:The non-Hodgkin's lymphomas 2, ed. by Magrath I, Oxford Univ Press, Oxford, 1997, p. 412
2) 成人T細胞白血病・リンパ腫, 木下研一郎編, 新興医学出版社, 東京, 2003
6) 鵜池直邦:変わりつつある悪性リンパ腫の治療-組織分類に基づく治療対応-菌状息肉腫/セザリー症候群. カレントテラピー 21:457-462, 2003
12) Kuzel TM, Hurria A, Samuelson E et al:Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906-911, 1996
15) 青木見佳子:血液疾患と皮膚病変 Ki-1リンパ腫 (CD30 positive T-cell lymphoproliferative disorders) -今日的な概念-. 血液・免疫・腫瘍 8:222-225, 2003
16) 桐生美麿:皮膚CD30陽性未分化大細胞性リンパ腫の診断と治療. MB Dernza 80:32-37, 2003
17) 山口素子:NK/T細胞リンパ腫. カレントテラピー 21:43-46, 2003
21) 新・悪性リンパ腫アトラス, 須知泰山ほか編, 文光堂, 東京, 2000
24) Kagami Y, Nakamura S, Suzuki R et al:A nodal γ/δ T-cell lymphoma with an association of Epstein-Barr virus. Am J Surg Pathol 21:729-736, 1997
26) Kaneko Y, Maseki N, Sakurai M et al:Characteristic karyotypic pattern in T-cell lymphoproliferative disorders with reactive "angioimmunoblastic lymphadenopathy with dysproteinemia-type"features. Blood 72:413-421, 1988
28) Shiota M, Nakamura S, Ichinohasama R et al:Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK:a distinct clinicopathologic entity. Blood 86:1954-1960, 1995
29) 畠清彦:未分化大細胞型リンパ腫- anaplastic largecell lymphoma-. カレントテラピー 21:467-471, 2003
30) Suzuki R, Kagami Y, Takeuchi K et al:Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood 96:2993-3000, 2000
32) Ho L, Aytac U, Stephens LC et al:In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30 + anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7:2031-2040, 2001
33) Wahl AF, Klussman K, Thompson JD et al:CD30 monoclonal antibody SGN-30 promotes arrest and DNA fragmentation in vitro and antitumor activity in models of Hodgkin's Cancer Res 62:3736-3742, 2002
35) 鈴宮淳司:末梢性細胞リンパ腫の病態と治療. 治療学 38:62-66, 2004
P.227 掲載の参考文献
1) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Homatopietic and Lymphoid Tissues, eds by Jaffe ES et al IARC Press, Lyon, 2001
5) Seitz V, Hummel M, Marafioti T et al:Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Stemberg cells of classic Hodgkin disease. Blood 95:3020-3024, 2000
11) Jox A, Zander T, Kuppers R et al:Somatic mutations within the untranslated regions of rearranged Ig genes in cause of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Blood 93:3964-3972, 1999
17) Emmerich F, Meiser M, Hummel M et al:Overexpression of I kappa B alpha without inhibition of NF-KB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94:3129-3134, 1999
18) Cabannes E, Khan G, Aillet F et al:Mutations in the IK Ba gene in Hodgkin's disease suggest a tumour suppressor role for IKBα. Oncogene 18:3063-3070, 1999
29) Hasenclever D, Diehl V, Armitage JO et al:The international prognostic factors project on advanced Hodgkin's disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506-1514, 1998
37) Horning SJ, Hoppe RT, Breslin S et al:Very Brief (8 week) chemotherapy and low dose (30 Gy) radiotherapy (RT) for limited stage Hodgkin`s disease:Preliminary results of the Stanford-Kaiser G4 study of Stanford V + RT. Blood 94 (suppl 1):S1O, 1999
53) Aleman BM, Raemaekers JM, Tirelli U et al; European Organization for Research and Treatment of Cancer Lymphoma Group:involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl. J Med 348:2396-2406, 2003
59) Schnell R, Staak O, Borchmann Pet al:A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30 + Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8:1779-1786, 2002
P.235 掲載の参考文献
6) World Health Organization Classification of tumours patholgy and genetics of tumours of hoematopoietic and lymphoid tissues 3, eds by jaffe ES et al, IARC Press, Lyon, 2001
16) 佐野量造:胃疾患の臨床病理, 医学書院, 東京, 1974
17) 斉藤大三, 小田一郎, 乾哲也ほか:H.pylory除菌と効果 内視鏡像からみた立場. Modern, Physician 22:757-760, 2002
19) Flieger D, Keller R, Fischbach W:Capsule endoscopyin Gastric Malt lymphoma and other gastrointestinal lymphomas. Gastroenterotogy 126:A621, 2004
23) 目良清美:胃原発 MALT リンパ腫に対する非外科的治療の多施設共同研究-中間解析結果報告から-. 癌の臨床 50:565-570, 2004
P.248 掲載の参考文献
2) Nishida K, Tamura A, Nakazawa Net al:The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526-534, 1997
3) Neoplastic diseases of the blood 4, eds. by Wiernik PH, Goldman JM, Dutcher JP et al, Cambridge University Press, Cambridge, 2003
4) Multiple myeloma and related disorders, eds. by Gahrton G, Durie BGM, Samson, DM, Arnold, London, 2004
5) Biology and management of multiple myoloma, ed. by Berenson JR, Humana Press, Totowa, 2004
6) 戸川敦:多発性骨髄腫 (改訂), 新興医学出版, 東京, 2002
9) 谷脇雅史, 西田一弘:MGUSの分子病態と予後因子. 血液・腫瘍科 46:155-160, 2003
10) 西田一弘, 谷脇雅史:IgH遺伝子の転座と新しい分類の可能性. 臨床血液 41:414-417, 2000
11) 谷脇雅史, 中澤直三, 西田一弘:骨髄腫におけるIgH遺伝子の染色体転座. 細胞 31:357-361, 1999
12) Nishida K, Taniwaki M, Misawa S et al:Non random rearrangement of chromosome 14 at band q32. 33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 49:1275-1281, 1989
13) Janssen JW, Vaandrager JW, Heuser T et al:Concurrent activation of a novel putative transforming gene, myeloma, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14) (q13;q32). Blood 95:2691-2698, 2000
17) Taniwaki M, Nishida K, Takashima T et al:Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84:2283-2290, 1994
22) Sawyer JR, Lukacs JL, Munshi N et al:Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92:4269-4278, 1998
23) 西田一弘:多発性骨髄腫. 造血器腫瘍アトラス, 阿部 達生編, 日本医事新報社, 東京, 2000, pp. 143-149
24) Drach J, Ackermann J, Fritz E et al:Presence of a p53gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802-809, 1998
25) 村上博和, 半田寛, 今井浩三ほか:日本骨髄腫研究会参加施設におけるサリドマイド治療の現状と成績. 臨床血液 45:468-472, 2004
34) Ibrahim A, Scher N, Williams G et al:Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394-2399, 2003

PART 3 合併症の診断と治療

P.282 掲載の参考文献
2) Specimen collection, transport, and processing:Bacteriology. In:Manual of Clinical Microbiology 6, eds. by Murray PR et al, ASM press, Washington, DC, 2003, pp. 286-330
4) David NG:日本語版サンフォード感染症治療ガイド 2004 (第34版), 出雲正剛ほか監修, ライフサイエンス出版, 東京, 2004, p. 114
P.288 掲載の参考文献
P.293 掲載の参考文献
1) Bristow MR, Billingham ME, Mason JW et al:Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873-879, 1978
5) 山本昇:心毒性. がん化学療法の副作用と対策, 西條 長宏監修, 中外医学社, 東京, 1998, pp. 122-131
7) Villani F, Galimberti M, Crippa F:Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 15:501-506, 1989
13) Goldberg MA, Antin JH, Guinan EC et al:Cyclophosphamide cardiotoxicity:an analysis of dosing as a risk factor. Blood 168:1114-1118, 1986
14) Beaiman SI, Petersen FB, Schor RA et al:Radionuclide ejection fraction in the evaluation of patients being considered for bone marrow transplantation:risk for cardiac toxicity. Bone Marrow Transplant 5:173-177, 1990

最近チェックした商品履歴

Loading...